

Controversies in AML

ANCONA • 16 GIUGNO 2023

SEEPOR HOTEL


Should AML patients in CR1 unfit for HSCT receive maintenance? NO

Giovanni Marconi - IRST IRCSS


Disclosures


	Consultant	Speaker bureau	Research support
Abbvie	x	x	x
Astellas	x	x	x
Astrazeneca		x	x
Daiichi Sankyo			x
Immunogen	x		
Menarini/Stemline	x	x	
Pfizer	x	x	x
Ryvu	x		
Servier		x	
Syros	x	x	
Takeda		x	

0




Should AML patients in CR1 unfit for HSCT receive maintenance? NO





personal






CBF,
NPM1


IDH1/2,
splicing
Other

MR,
TP53




personal





Wei, NEJM 2022

Duration of MRD Negativity



No. at risk

Oral AZA

Placebo

221

112

79

62

33

15

2

0

216

74

45

32

19


14

2

0

Robotz, Blood 2022


Overall Survival: MRD-



No. at risk

Oral AZA	133	123	106	87	74	54	39	28	19	14	11	3	1	0
Placebo	111	97	77	62	55	37	20	16	12	10	8	5	1	0


Overall Survival: MRD+



No. at risk

Oral AZA	103	88	60	44	39	31	19	8	6	3	3	2	0
Placebo	116	82	46	31	24	20	13	11	7	4	3	1	0


Robotz, Blood 2022




de novo AML





AML Polyclonal




AML MR




No eradication




personal





personal





Vodnala, Science, 2019

Grazie per l'attenzione



giovanni.marconi@irst.emr.it

T: +39-3207593015

 SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico

 ISTITUTO
ROMAGNOL
PER LO STUDIO
DEI TUMORI
DINO AMADORI




GIOVANNI M.
Medico




CINZIA C.
Infermiera



GIORGIO V.
Volontario



CLAUDIA B.
Guarita



ALESSIA A.
Familiare



CHIARA S.
Ricercatrice